Welcome to our dedicated page for INmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on INmune Bio stock.
INmune Bio Inc. (NASDAQ: INMB) is a clinical-stage biotechnology company focused on developing novel immunotherapies that leverage the body’s innate immune system to fight cancer and other diseases. The company has a robust pipeline of product candidates, including INKmune™, INB03™, XPro™, and LIVNate™.
The company’s leading product, INKmune™, is designed to prime a patient’s natural killer (NK) cells to target and eliminate cancer cells that remain after initial treatment, thereby preventing relapse. By enhancing the functionality of NK cells, INKmune™ aims to boost the body’s ability to control residual disease, potentially extending patient survival.
INmune Bio’s INB03™ is a dominant-negative tumor necrosis factor (DN-TNF) inhibitor targeting high-risk breast cancers expressing MUC4 and triple-negative breast cancer (TNBC). Recent data presented at the American Association of Cancer Research in San Diego highlighted INB03™’s potential to decrease T cell and macrophage immune checkpoint proteins and reduce the metastatic potential of TNBC.
The company has also achieved significant milestones with XPro™, a treatment for Alzheimer’s Disease. INmune Bio recently announced the successful completion of the extended stability validation for continuous storage of XPro™ in solution, confirming its 24-month stability. The company is preparing for Phase III trials and commercial applications, leveraging established global distribution systems.
In addition, INmune Bio has entered into definitive agreements for the sale and purchase of nearly 1 million shares of its common stock and warrants, generating gross proceeds of approximately $9.7 million. These funds are earmarked to support ongoing clinical trials, including the Phase 2 trial for Alzheimer’s Disease and the Phase 1 trial for metastatic castration-resistant prostate cancer (mCRPC) using INKmune™.
The company’s management has focused on ensuring the safety and efficacy of their treatments. Recently, INKmune™ has shown promising results in initial clinical trials for mCRPC, with no significant adverse events reported, and approvals to proceed with further dosing cohorts.
For investors and stakeholders, INmune Bio provides a unique investment opportunity, combining cutting-edge science with a commitment to improving patient outcomes through innovative immunotherapy solutions. For more information, visit www.inmunebio.com.
INmune Bio, Inc. (NASDAQ: INMB) presented promising data on INKmune, a treatment aimed at solid tumors, at the Innate Killer Summit Europe on October 19, 2022. Solid tumors account for 90% of adult cancers, yet most therapies target liquid tumors. INKmune enhances the ability of Natural Killer (NK) cells to attack NK-resistant cancer types, including prostate, ovarian, renal, and nasopharyngeal cancers. Notably, INKmune-primed NK cells showed a 66% lysis rate on DU145 prostate cells compared to less than 4% for unprimed cells. This data supports the transition of INKmune trials towards solid tumors, potentially benefiting over 4 million patients in the US.
INmune Bio (NASDAQ: INMB) announced that RJ Tesi, M.D., CEO, will present at two upcoming conferences: the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 4:00 pm ET in New York, and the Baird Global Healthcare Conference on September 14, 2022, at 3:45 pm ET. Both events will include one-on-one meetings with management. The company focuses on creating treatments that leverage the innate immune system against diseases, with products in clinical trials targeting multiple conditions.
INmune Bio reported its Q2 2022 financial results and business update, highlighting the dosing of the first patient in a Phase II trial for Alzheimer’s using XPro™. The FDA review concerning a clinical hold on XPro1595 is ongoing. The company has sufficient doses for ongoing trials and has presented promising data on XPro™ and INB03 at various conferences. Financially, INmune posted a net loss of $6.8 million, slightly up from $6.7 million last year, with $61.2 million in cash as of June 30, 2022. Shares outstanding are approximately 17.9 million.
INmune Bio, Inc. will host a conference call on August 3, 2022 at 4:30 PM ET to discuss its Q2 2022 results and provide a corporate update. Participants can join by dialing 1-877-407-0784 (or 1-201-689-8560 internationally) and entering conference ID 13728540. The live webcast will also be available. INmune Bio focuses on developing therapies targeting the innate immune system for diseases such as cancer and Alzheimer's.
INmune Bio (NASDAQ: INMB) announces participation in the Alzheimer's Association International Conference and BTIG Biotechnology Conference, focusing on innovative therapies for Alzheimer's disease. RJ Tesi, Ph.D., will engage in panel discussions about novel treatments and the role of inflammation in Alzheimer's. The AAIC panel is part of a program aimed at funding cutting-edge research. The company will also release videos highlighting neuroinflammation's role in disease. INmune Bio's XPro™ aims to reduce neuroinflammation, potentially benefiting Alzheimer's patients.
INmune Bio, Inc. (NASDAQ: INMB) has received U.S. Patent No. 11,365,229 for methods of treating neurological diseases with Dominant Negative Tumor Necrosis Factor (DN-TNF) variants, such as XPro™, allowing these treatments to cross the blood-brain barrier. This patent is valid until September 10, 2033, with a possible extension. The company believes this patent enhances its intellectual property and supports its ongoing clinical trials for conditions like Alzheimer’s disease, treatment-resistant depression, and ALS.
INmune Bio (NASDAQ: INMB) presented data at the HER2 Targeted Therapy Summit, demonstrating that INB03™ effectively decreases MUC4 expression in trastuzumab-resistant HER2+ breast cancer models. This treatment not only reverses resistance to trastuzumab but also enhances the immunologically active tumor microenvironment (TME). Key findings indicate a significant increase in activated natural killer (NK) cells and anti-tumor macrophages when combining INB03 with trastuzumab. The company aims to advance INB03 into a Phase II trial, aiming for improved outcomes in patients with breast cancer resistant to current treatments.
On May 23, 2022, INmune Bio (NASDAQ: INMB) announced that the FDA placed their Investigational New Drug (IND) application for XPro™ in Alzheimer's treatment on clinical hold, pending additional information regarding Chemistry Manufacturing and Controls (CMC). The official hold letter is expected in approximately 30 days. Meanwhile, the Phase 2 trial for XPro™ continues to enroll patients in Australia. XPro™ is designed to inhibit soluble TNF, potentially reducing neuroinflammation in neurologic diseases.
INmune Bio (NASDAQ: INMB) announced that David Moss, CFO, will present at the H.C. Wainwright Global Hybrid Investment Conference from May 23-26, 2022, at the Fontainebleau Hotel in Miami Beach, FL. The presentation is scheduled for May 24, 2022, at 10:00 AM ET. Moss will also be available for one-on-one meetings, which can be requested through the conference registration link. INmune Bio is focused on immunological therapies targeting the innate immune system, with several candidates in clinical trials for various conditions.
INmune Bio announced that data on XPro™'s ability to promote remyelination in a cuprizone model of multiple sclerosis will be presented on May 10, 2022. Research by Professor Lesley Probert reveals that XPro™ enhances macrophage phagocytosis of myelin debris, aiding in the remyelination process. Previous findings have indicated that XPro™ promotes remyelination in Alzheimer’s patients after a successful Phase I trial. This represents a promising development in neurodegenerative disease treatment.
FAQ
What is the current stock price of INmune Bio (INMB)?
What is the market cap of INmune Bio (INMB)?
What is INmune Bio Inc.'s primary focus?
What is INKmune™?
What recent achievements has INmune Bio reported?
What is the significance of INB03™?
How does INmune Bio plan to use the recent funding?
What are the key components of INmune Bio’s product platforms?
What ongoing clinical trials are INmune Bio conducting?
How does INKmune™ work?
Is INmune Bio’s technology approved by the FDA?
How can investors get more information about INmune Bio?
